세계의 급성 간헐성 포르피린증 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Acute Intermittent Porphyria Market is presumed to reach the market size of nearly USD 8.41 Million by 2032 from USD 5.63 Million in 2023 with a CAGR of 4.56% under the study period 2024-2032.

Acute intermittent porphyria (AIP) is a rare genetic disorder that affects heme production, a hemoglobin component. Sudden attacks of abdominal pain, vomiting, neurological disturbances, and psychological symptoms like anxiety or hallucinations characterize it. Certain medications, hormonal changes, or dietary factors often trigger these attacks. Diagnosis involves detecting elevated levels of porphobilinogen and delta-aminolevulinic acid in the urine. Management includes avoiding triggers, symptomatic treatment during attacks, and sometimes the use of heme infusions.

MARKET DYNAMICS

The acute intermittent porphyria market is influenced by the increasing awareness and diagnosis of rare genetic disorders, leading to improved disease management and treatment options. Additionally, advancements in medical research & genetic testing technologies enable healthcare providers to understand better the underlying causes and mechanisms of acute intermittent porphyria, facilitating earlier detection and intervention. Moreover, collaborations among pharmaceutical companies and academic institutions drive research & development efforts to discover novel therapies and improve treatment options. However, challenges such as limited treatment options and the complexity of managing acute attacks may impact the market growth in the coming years. As healthcare providers and researchers strive for better outcomes and quality of life for patients with rare diseases, the demand for effective treatments and management strategies for acute intermittent porphyria is expected to drive further market development.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Acute Intermittent Porphyria. The growth and trends of Acute Intermittent Porphyria industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Acute Intermittent Porphyria market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Diagnosis

• Blood Test
• Urine Test
• DNA Test
• Serum Test

By Treatment

• Gonadotropin-Releasing Hormone Analogues
• Prophylactic Hematin Infusions

By End-user

• Hospitals
• Clinics
• Research Centers

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Acute Intermittent Porphyria market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Acute Intermittent Porphyria market include Alnylam Pharmaceuticals Inc., Clinuvel Pharmaceuticals Ltd., BioMarin Pharmaceutical Inc., Recordati, Quest Diagnostics, Invitae Corp., Laboratory Corporation Of America Holdings (Labcorp), ARUP Laboratories. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ACUTE INTERMITTENT PORPHYRIA - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Diagnosis
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY DIAGNOSIS

• 5.1. Overview By Diagnosis
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Diagnosis
• 5.4. Blood Test Historic and Forecast Sales By Regions
• 5.5. Urine Test Historic and Forecast Sales By Regions
• 5.6. DNA Test Historic and Forecast Sales By Regions
• 5.7. Serum Test Historic and Forecast Sales By Regions

6. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY TREATMENT

• 6.1. Overview By Treatment
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Treatment
• 6.4. Gonadotropin-Releasing Hormone Analogues Historic and Forecast Sales By Regions
• 6.5. Prophylactic Hematin Infusions Historic and Forecast Sales By Regions

7. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY END-USER

• 7.1. Overview By End-user
• 7.2. Historical and Forecast Data
• 7.3. Analysis By End-user
• 7.4. Hospitals Historic and Forecast Sales By Regions
• 7.5. Clinics Historic and Forecast Sales By Regions
• 7.6. Research Centers Historic and Forecast Sales By Regions

8. GLOBAL ACUTE INTERMITTENT PORPHYRIA MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE ACUTE INTERMITTENT PORPHYRIA COMPANIES

• 9.1. Acute Intermittent Porphyria Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF ACUTE INTERMITTENT PORPHYRIA INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Alnylam Pharmaceuticals Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Clinuvel Pharmaceuticals Ltd.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. BioMarin Pharmaceutical Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Recordati
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Quest Diagnostics
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Invitae Corp.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Laboratory Corporation Of America Holdings (Labcorp)
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. ARUP Laboratories
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies